Patent ID: 6166031
Filing Date: 2000-12-26
Classification: A61K,A61P

Abstract:
A method of inhibiting 5-lipoxygenase and/or blocking leukotriene D4 receptors in a mammal in need of such inhibition and/or blocking which comprises administering to said mammal a 5-lipoxygenase inhibiting and/or leukotriene D4 receptor blocking amount of a racemic or optically active compound having the structural formula ##STR9## wherein n is 0 or 1;X is CH.sub.2 ;X.sup.1 is CH.sub.2 ;Y and Y.sup.1 taken together form .dbd.O, or Y is hydrogen and Y.sup.1 is hydroxy;Z is CH.sub.2 ;Z.sup.1 is CH;R is 2-, 3- or 4-quinolyl, said group being mono- or disubstituted on carbon with the same or different substituents which are bromo, chloro, fluoro, (C.sub.1 -C.sub.4)alkyl, trifluoromethyl, hydroxy, hydroxymethyl or (C.sub.1 -C.sub.4)alkoxy, or substituted on adjacent carbons with trimethylene, tetramethylene, --CH.sub.2 --O--CH.sub.2, or --O--CH.sub.2 --O; andR.sup.1 is (C.sub.7 -C.sub.10)bicycloalkyl, (C.sub.4 -C.sub.10)cycloalkylalkyl, (C.sub.8 -C.sub.11)bicycloalkylalkyl, or one said groups mono- or disubstituted with the same or different groups which are fluoro, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, carboxy or -carbonyl;a pharmaceutically acceptable acid addition salt thereof; ora pharmaceutically acceptable cationic salt when the compound contains a carboxy group wherein the mammal is a human suffering from a condition selected from the group consisting of asthma, arthritis, psoriasis, and gastrointestinal distress, and said compound is administered to prevent or relieve the symptoms of said condition.